New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 27, 2013
06:25 EDTNVS, BDX, TEVA, HSPInjectable drug shortages may ease with rising interest, WSJ reports
The shortage of injectable drugs used by hospitals could ease as more healthcare companies look to become new manufacturers, Wall Street Journal reports. Becton Dickinson (BDX) became the latest player in the $7B market with yesterday's approval for an antihistamine, the paper adds. Reference Link
News For BDX;HSP;TEVA;NVS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 1, 2015
08:01 EDTTEVATeva CEO: Pharma industry undergoing “very big shakeup,” Globes reports
Subscribe for More Information
05:16 EDTNVSNovartis division Alcon receives CE Mark for AcryS of IQ Aspheric IOL
Subscribe for More Information
June 30, 2015
08:27 EDTTEVAPerrigo deal for Roxane would make Mylan fight harder, says Citi
Subscribe for More Information
05:32 EDTNVSNovartis launches first Apple Watch app for visually impaired people
Novartis Pharmaceuticals (NVS) announced the release of new features for its ViaOpta applications, and the extension for use with smart watches. The discreet, hands-free nature of using ViaOpta app with wearable devices, such as Apple Watch (AAPL) and Android Wear (GOOG), provides users with an experience that seamlessly fits into their existing routines allowing those with visual impairments to navigate daily life with even greater ease.
June 29, 2015
10:09 EDTBDXOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:35 EDTNVSAnacor announces amendment to KERYDIN commercialization agreement
Subscribe for More Information
06:52 EDTBDXBecton Dickinson upgraded to Buy from Neutral at UBS
Subscribe for More Information
05:15 EDTNVSNovartis acquires Spinifex Pharmaceuticals, terms not disclosed
Novartis announced that it has entered into an agreement to acquire Spinifex Pharmaceuticals. Spinifex Pharmaceuticals is a U.S. and Australian-based, privately held development stage company, focused on developing a peripheral approach to treat neuropathic pain such as EMA401, a novel angiotensin II Type 2 receptor, or AT2R, antagonist. Financial terms were not disclosed.
June 28, 2015
12:22 EDTBDXBD Medical says reusable sharps containers lead to higher rates of C. diff
Subscribe for More Information
June 26, 2015
10:38 EDTTEVACourt revives lawsuit over GlaxoSmithKline Lamictal drug, Bloomberg reports
Subscribe for More Information
07:44 EDTNVSNovartis drug Farydak recommended by CHMP for EU approval
Subscribe for More Information
June 25, 2015
14:02 EDTNVSNovartis initiated with a Buy at HSBC
Price target CHF 115.
13:59 EDTTEVATeva initiated with a Hold at HSBC
Subscribe for More Information
12:52 EDTTEVAEU to decide by July 29 on Mylan's bid for Perrigo, Reuters reports
Subscribe for More Information
08:05 EDTTEVATeva, Active Biotech say patient enrollment finalized for CONCERTO trial
Subscribe for More Information
June 24, 2015
08:04 EDTTEVATeva launches PainMatters.com to support ‘responsible pain management’
Subscribe for More Information
07:06 EDTHSPHospira: FDA deems India facility 'acceptable' for manufacturing
Hospira said in a regulatory filing that on June 23, Hospira Healthcare India Private Limited, a subsidiary of Hospira, received official notification from the U.S. FDA that the inspection of the Visakhapatnam, India facility was deemed acceptable for the manufacture of finished dosage drugs. As a result of this action, the company may receive U.S. product approvals from this facility in the future. As was previously reported, the FDA conducted a pre-approval inspection of the Vizag facility from February 16 to February 25, which resulted in the issuance of a Form 483 containing 14 observations. Hospira responded to the Form 483 on March 18, and submitted additional support documentation on May 29. The inspection was found to be acceptable following the FDA’s review of the company’s responses and support documentation. The company has begun limited commercial production at the facility.
June 23, 2015
14:16 EDTTEVABMO Capital sees strong fundamentals in Perrigo regardless of Mylan deal
Shares of Perrigo (PRGO) are trading higher intraday after BMO Capital Markets initiated coverage of the stock with an Outperform rating. The research firm is bullish on the shares regardless of whether Mylan's bid for the company succeeds, saying Perrigo is well-positioned to ride momentum in reduced-price healthcare. WHAT'S NEW: BMO Capital Markets' David Maris initiated coverage of Perrigo with an Outperform rating and a $246 price target. Maris cited the company's 70%-plus market share in store- and private-label brands, as well as its roughly $1B annual sales in the generics space. The analyst believes Perrigo will see continued benefit from larger trends driving consumer-centric healthcare and the curtailing of medical costs. WHAT'S NOTABLE: BMO Capital Markets noted that two upcoming Tysabri-related events are not accounted for by the Street, giving rise to a "significant" undervaluing of the shares. Mylan (MYL) has submitted multiple unsolicited offers for Perrigo, and while the likelihood of the deal seems low given Perrigo's numerous rejections and Teva's (TEVA) 4.61% blocking stake in Mylan. BMO Capital remarked that a failed deal should see "limited downside" for Perrigo. There could certainly be near-term volatility if a Mylan agreement doesn't materialize, but the analyst was confident in the well-positioned company's ability to deliver on both earnings per share and cash flow. PRICE ACTION: Shares of Perrigo are up nearly 2% in afternoon trading. The company saw a nearly 25% leap following Mylan's initial offer on April 8, though it has since dipped from that high.
08:49 EDTTEVAMylan CFO to meet with Tel Aviv bourse head Wednesday, Reuters says
Subscribe for More Information
June 21, 2015
19:53 EDTTEVAMylan CEO says Teva's 4.61% stake may be 'illegal,' Bloomberg reports
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use